- Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- Corcept Completes Enrollment in Phase 4 CATALYST Trial
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
- Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
- Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
- Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
- Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
More ▼
Key statistics
On Tuesday, Corcept Therapeutics Inc (CORT:NAQ) closed at 31.61, -7.78% below its 52-week high of 34.28, set on Sep 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 28.05 |
---|---|
High | 32.83 |
Low | 27.30 |
Bid | 31.30 |
Offer | 34.00 |
Previous close | 31.61 |
Average volume | 1.03m |
---|---|
Shares outstanding | 104.11m |
Free float | 92.26m |
P/E (TTM) | 29.56 |
Market cap | 3.29bn USD |
EPS (TTM) | 1.07 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼